Sage Therapeutics has seen another clinical trial go up in smoke. | Sage Therapeutics has seen another clinical trial go up ...

Sage has decided to discontinue the development of dalzanemdor in Alzheimer’s disease. A study of the candidate in Huntington ...

Shares of Sage Therapeutics, Inc. SAGE were down 4.3% on Oct. 8 after the company announced disappointing top-line data from ...

Sage plans to stop developing dalzanemdor (SAGE-718) for Alzheimer’s after it failed to boost cognitive function in a Phase 2 ...

Sage Therapeutics is a sell due to failure of SAGE-324 in essential tremors and dalzanemdor's poor performance in Parkinson's ...

The biopharmaceutical company isn’t planning further clinical development of dalzanemdor to treat Alzheimer’s.

Sage Therapeutics said its Phase 2 trial of dalzanemdor in patients with mild cognitive impairment or mild dementia due to ...

Sage Therapeutics' dalzanemdor failed to show significant results in Phase 2 Alzheimer's study. The company discontinues ...

(RTTNews) - Sage Therapeutics, Inc. (SAGE) Tuesday said its Phase 2 LIGHTWAVE study to evaluate dalzanemdor in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's ...

Sage Therapeutics announces reorganization, including layoffs and pipeline changes, to support the launch of Zurzuvae. Focus ...

Wedbush lowered the firm’s price target on Sage Therapeutics to $8 from $9 and keeps a Neutral rating on the shares. The firm ...

San Diego, California--(Newsfile Corp. - October 10, 2024) - Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sage Therapeutics, Inc. (NASDAQ: SAGE) securities between April ...